Literature DB >> 31095701

Challenges in IBD Research: Precision Medicine.

Lee A Denson1, Mark Curran2, Dermot P B McGovern3, Walter A Koltun4, Richard H Duerr5, Sandra C Kim6, R Balfour Sartor7, Francisco A Sylvester8, Clara Abraham9, Edwin F de Zoeten10, Corey A Siegel11, Richéal M Burns12, Angela M Dobes13, Nataly Shtraizent13, Gerard Honig13, Caren A Heller13, Andrés Hurtado-Lorenzo13, Judy H Cho14.   

Abstract

Precision medicine is part of five focus areas of the Challenges in IBD research document, which also includes preclinical human IBD mechanisms, environmental triggers, novel technologies, and pragmatic clinical research. The Challenges in IBD Research document provides a comprehensive overview of current gaps in inflammatory bowel diseases (IBD) research and delivers actionable approaches to address them. It is the result of a multidisciplinary input from scientists, clinicians, patients, and funders, and represents a valuable resource for patient centric research prioritization. In particular, the precision medicine section is focused on highlighting the main gap areas that must be addressed to get closer to treatments tailored to the biological and clinical characteristics of each patient, which is the aim of precision medicine. The main gaps were identified in: 1) understanding and predicting the natural history of IBD: disease susceptibility, activity, and behavior; 2) predicting disease course and treatment response; and 3) optimizing current and developing new molecular technologies. Suggested approaches to bridge these gaps include prospective longitudinal cohort studies to identify and validate precision biomarkers for prognostication of disease course, and prediction and monitoring of treatment response. To achieve this, harmonization across studies is key as well as development of standardized methods and infrastructure. The implementation of state-of-the-art molecular technologies, systems biology and machine learning approaches for multi-omics and clinical data integration and analysis will be also fundamental. Finally, randomized biomarker-stratified trials will be critical to evaluate the clinical utility of validated signatures and biomarkers in improving patient outcomes and cost-effective care.
© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; biological signature; biomarker; deep phenotyping; patient stratification; precision medicine; ulcerative colitis

Mesh:

Substances:

Year:  2019        PMID: 31095701     DOI: 10.1093/ibd/izz078

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  28 in total

Review 1.  Challenges in IBD Research: Novel Technologies.

Authors:  Manish Dhyani; Nitin Joshi; Willem A Bemelman; Michael S Gee; Vijay Yajnik; André D'Hoore; Giovanni Traverso; Mark Donowitz; Gustavo Mostoslavsky; Timothy K Lu; Neil Lineberry; Heiko G Niessen; Dan Peer; Jonathan Braun; Conor P Delaney; Marla C Dubinsky; Ashley N Guillory; Maria Pereira; Nataly Shtraizent; Gerard Honig; David Brent Polk; Andrés Hurtado-Lorenzo; Jeffrey M Karp; Fabrizio Michelassi
Journal:  Inflamm Bowel Dis       Date:  2019-05-16       Impact factor: 5.325

Review 2.  Challenges in IBD Research: Environmental Triggers.

Authors:  Shuk-Mei Ho; James D Lewis; Emeran A Mayer; Scott E Plevy; Emil Chuang; Stephen M Rappaport; Kenneth Croitoru; Joshua R Korzenik; Jeffrey Krischer; Jeffrey S Hyams; Richard Judson; Manolis Kellis; Michael Jerrett; Gary W Miller; Melanie L Grant; Nataly Shtraizent; Gerard Honig; Andrés Hurtado-Lorenzo; Gary D Wu
Journal:  Inflamm Bowel Dis       Date:  2019-05-16       Impact factor: 5.325

Review 3.  The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease.

Authors:  Christopher A Lamb; Aamir Saifuddin; Nick Powell; Florian Rieder
Journal:  Gastroenterology       Date:  2022-01-04       Impact factor: 22.682

4.  Application of Artificial Intelligence to Clinical Practice in Inflammatory Bowel Disease - What the Clinician Needs to Know.

Authors:  David Chen; Clifton Fulmer; Ilyssa O Gordon; Sana Syed; Ryan W Stidham; Niels Vande Casteele; Yi Qin; Katherine Falloon; Benjamin L Cohen; Robert Wyllie; Florian Rieder
Journal:  J Crohns Colitis       Date:  2022-03-14       Impact factor: 10.020

5.  C-Reactive Protein/Albumin Ratio at Diagnosis of Pediatric Inflammatory Bowel Disease: A Retrospective Multi-Center Study.

Authors:  Aleksandra Glapa-Nowak; Mariusz Szczepanik; Aleksandra Banaszkiewicz; Jarosław Kwiecień; Anna Szaflarska-Popławska; Urszula Grzybowska-Chlebowczyk; Marcin Osiecki; Jarosław Kierkuś; Marcin Dziekiewicz; Jarosław Walkowiak
Journal:  Med Sci Monit       Date:  2022-09-14

6.  Decreased Enteric Bacterial Composition and Diversity in South American Crohn's Disease Vary With the Choice of Treatment Strategy and Time Since Diagnosis.

Authors:  Angélica Cruz-Lebrón; Leticia D'argenio Garcia; Aarthi Talla; Samira Joussef-Piña; Miguel E Quiñones-Mateu; Rafick-Pierre Sékaly; Karina Inacio Ladislau de Carvalho; Alan D Levine
Journal:  J Crohns Colitis       Date:  2020-07-09       Impact factor: 9.071

7.  Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases.

Authors:  Gerard Honig; Caren Heller; Andrés Hurtado-Lorenzo
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

8.  Serum biomarkers confirming stable remission in inflammatory bowel disease.

Authors:  Christoph Kessel; Miha Lavric; Toni Weinhage; Markus Brueckner; Sytze de Roock; Jan Däbritz; Jakob Weber; Sebastiaan J Vastert; Dirk Foell
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379

Review 9.  Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?

Authors:  Raphael P Luber; Sailish Honap; Georgina Cunningham; Peter M Irving
Journal:  Front Med (Lausanne)       Date:  2019-11-28

Review 10.  Potential for Standardization and Automation for Pathology and Endoscopy in Inflammatory Bowel Disease.

Authors:  Sana Syed; Ryan W Stidham
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 7.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.